Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden

BACKGROUND: Tolvaptan is the only vasopressin V(2) receptor antagonist licensed by the European Medicines Agency for the treatment of hyponatraemia (HN) secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). We have investigated the cost-effectiveness of tolvaptan versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamookeeah, Clare, Robinson, Paul, O’Reilly, Karl, Lundberg, Johan, Gisby, Martin, Ländin, Michael, Skov, Jakob, Trueman, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867540/
https://www.ncbi.nlm.nih.gov/pubmed/27184496
http://dx.doi.org/10.1186/s12902-016-0104-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867540/
https://www.ncbi.nlm.nih.gov/pubmed/27184496
http://dx.doi.org/10.1186/s12902-016-0104-z

Ejemplares similares